Exchange listing deficiency and compliance notices under 8-K Item 3.01.
SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“(the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,032,002, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of this report, the Company does not meet either of the alternative Nasdaq”
Offerpad Solutions Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“November 15, 2022, Offerpad Solutions Inc. (the “Company,” “we,” “us” or “our”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE. On November 16, 2022, the Company notified the NYSE that it intends to cure the stock price deficiency and to return to compliance with th”
Horizon Acquisition Corp II received a nyse deficiency notice notice regarding market value (rules 802.01B).
“November 14, 2022, Horizon Acquisition Corporation II (the “ Company ”) received an e-mail from the New York Stock Exchange (the “ NYSE ”) stating that the NYSE was assessing the Company’s ability to meet the requirements of Section 802.01B of the NYSE’s Listed Company Manual. That Section requires a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly held shares (a “ public float ”) over a consecutive 30 trading day period of at least $40,000,000. The e-mail referred to the redemptions of the Company’s Class A ordinary shares i”
Mediaco Holding Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 15, 2022, MediaCo Holding Inc. (the “Company”) received a deficiency letter (the “Nasdaq Letter”) from the staff of the Nasdaq Listing Qualifications Department (the “Staff”) stating that because the Company had reported stockholders’ equity of $1,982,000 in its Quarterly Report on Form 10-Q for the period ended September 30, 2022, the Company no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires a minimum $2.5 million stockholders’ equity and thus the Company's Class A common stock (listed on The Nasdaq Capital Market) would be subject to delisting unless the Comp”
Baudax Bio, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 15, 2022, Baudax Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. On its quarterly report for the quarter ended September 30, 2022, the Company reported stockholders’ equity of ($19,540,000), and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the Company”
BONK, INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“previously reported, on June 23, 2022, Jupiter Wellness Inc. (the “Company”) received a notice (the “Notice”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because it failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days. Since then, the Staff has determined that for the last 10 consecutive business days, from November 4, 2022, to November 17, 2022, the closing bid price of the Company’s”
Eargo, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 15, 2022, the Company received a letter from Nasdaq indicating that, since the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022 reported stockholders’ equity of ($36,324,000), the Company no longer complies with Nasdaq Listing Rule 5450(b)(1)(A), which provides that companies listed on the Nasdaq Global Market are required to maintain a minimum of $10,000,000 in stockholders’ equity for continued listing. The Company intends to submit a plan to regain compliance to Nasdaq by no later than December 30, 2022. Forward-Looking Statements This Current Repor”
Eargo, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“November 17, 2022, Eargo, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company’s common stock (the “Common Stock”) had closed below Nasdaq’s $1.00 per share minimum bid price requirement for 30 consecutive business days, the Company no longer complies with Nasdaq Listing Rule 5450(a)(1) for continued listing. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until May 16, 2023 (the “Compliance Date”), to regain compliance. If at any”
Hyzon Motors Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“November 16, 2022, from the Nasdaq Listing Qualifications Department ("Nasdaq") indicating that the Company remains in non-compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. As previously disclosed on Form 8-K filed with the SEC on August 18, 2022, on August 16, 2022, the Company previously received a notice from Nasdaq indicating that as a result of not having timely filed its Quarterly Report on Form 10-Q for the peri”
Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 15, 2022, Applied Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”) does not satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million (the “Stockholders’ Equity Requirement”). As reported in its Form 10-Q, the Company’s stockholders”
Vislink Technologies, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“November 17, 2022, the Company received a letter from Nasdaq advising that the Company had been granted an additional 180-day grace period extension until May 15, 2023 to regain compliance with the minimum bid price requirement and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the minimum bid price requirement. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Rule, including initiating a reverse stock split. The Company has filed w”
SRAX, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“November 16, 2022, SRAX, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ending September 30, 2022 with the Securities and Exchange Commission (“SEC”) could serve as an additional basis for delisting under Nasdaq Listing rule 5250(c)(1) (the “Filing Requirement”). On October 12, 2022, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2021 with the SEC; however, the Company has not yet filed i”
OTONOMY, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii)).
“November 14, 2022, Otonomy, Inc. (the “Company”) received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Staff has determined to delist the Company’s securities unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Staff’s determination was due to the Company’s securities having a closing bid price of less than $0.10 per share for the preceding ten consecutive trading days, in contravention of Nasdaq Listing Rule 5810(c)(3)(A)(iii). The Company intends to timely request a hearin”
HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).
“November 18, 2022, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until January 2, 2023, to submit a plan to”
Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“November 16, 2022, the Company received written notice (the “Bid Price Notice” and, together with the Equity Notice, the “Notices”) from Nasdaq notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notices have no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market and the Company’s common s”
Ayala Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 10, 2022, Ayala Pharmaceuticals, Inc. (the “Company”) received written notice (the “Equity Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10 million. As reported on its Form 10-Q, the Company’s stockholders’ equity as of S”
HF Foods Group Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).
“10-Q for the three months ended June 30, 2022 (the “Q2 2022 Form 10-Q”, and, together with the Form 10-K, the Q1 2022 Form 10-Q and the Q2 2022 Form 10-Q, the “Delinquent Reports”), the Company is not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The notification letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. As previously disclosed, on September 27, 2022, the Company received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualific”
Investar Holding Corp received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).
“November 16, 2022, the Board elected Rose J. Hudson to serve as an independent director and a member of the Audit Committee of the Board. As a result, the Company is in compliance with the Audit Committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) at the time of this filing. Currently, the Audit Committee consists of the three independent directors.”
Accelerate Acquisition Corp. received a nyse delisting notice notice regarding other (rules 802.01D).
“November 15, 2022, the New York Stock Exchange (the “NYSE”) notified the Company, and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants from the NYSE and that trading in the Company’s warrants would be suspended immediately, due to trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. As a result of the expected expiration of the warrants described above, the Company does not intend to appeal the NYSE’s determination. Forward-Looking Statements This Current Report on Form 8-K includes certain forward-looking stat”
Kismet Acquisition Three Corp. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).
“November 10, 2022, Kismet Acquisition Three Corp. (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “”
Latch, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).
“November 14, 2022, Latch, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Third Quarter Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) by the required due date. As previously reported by the Company in it”
Aprea Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5450(b)(1)(A)).
“set forth in Listing Rule 5450(b)(1)(A) (the “Rule”). Based on the Company’s Form 10-Q for the period ended September 30, 2022, evidencing stockholders’ equity of approximately $26.6 million, the Staff has determined that the Company has regained compliance with the Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant”
Eargo, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A)).
“November 15, 2022, Eargo, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, since the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2022 reported stockholders’ equity of ($36,324,000), the Company no longer complies with Nasdaq Listing Rule 5450(b)(1)(A), which provides that companies listed on the Nasdaq Global Market are required to maintain a minimum of $10,000,000 in stockholders’ equity for continued listing. Under the Nasdaq Listing Rules, the Company has 45 calendar”
Cosmos Health Inc. received a nasdaq delisting notice notice regarding minimum bid price.
“Form 25-NSE with the SEC to remove the Company’s securities from listing and registration on the Nasdaq Stock Market. Although there is no assurance, we expect that the shareholder proposal at our scheduled December 2, 2022 Annual Shareholders Meeting, for which we have obtained a quorum, to provide the Board of Directors with the discretion to effect a reverse stock split, will enable us to regain compliance with Nasdaq’s minimum bid-price requirement for continued listing on the Nasdaq Capital Market.”
Cosmos Health Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5810(c)(3)(A)(ii)).
“November 10, 2022, Cosmos Holdings Inc. (the “Company”) received a non-compliance letter from the Nasdaq Stock Market for its failure to maintain a minimum closing bid price of $0.10 per share for ten (10) consecutive business days in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii). Pursuant to a prior non-compliance letter from Nasdaq dated July 26, 2022, the Company had until January 23, 2023 to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten (10) consecutive trading days. The Staff has determined to suspend trading of the”
IMPAC MORTGAGE HOLDINGS INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i)).
“s not in compliance with Section 1003(a)(i) of the NYSE American Company Guide, which requires an issuer to have stockholders'”
IMPAC MORTGAGE HOLDINGS INC received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i)).
“tionally, the Acceptance Letter notified the Company that the Company was not in compliance with a further NYSE American continued listing standard relating to stockholders’ equity (“ Deficiency Notice ”). Specifically, the Acceptance Letter stated that the Company is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide, which requires an issuer to have stockholders' equity of at least $2,000,000 if such issuer has sustained losses from continuing operations and/or net losses in two of its three most recent fiscal years. The Company reported a stockholder’s deficit of (”
Ever-Glory International Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“of The NASDAQ Stock Market LLC (“ Nasdaq ”) notifying the Company that the minimum bid price per share for its common stock has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on Nasdaq. Under the Nasdaq Listing Rules, the Company has until May 3, 2023 to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s common stock”
Hyperfine, Inc. received a nasdaq noncompliance notice notice regarding board independence (rules 5605(b)(1), 5615(c)).
“November 7, 2022. However, the Company’s notice to Nasdaq was in error. As previously disclosed, the Company is relying on the controlled company exemption in Nasdaq Listing Rule 5615(c), which exempts controlled companies (defined as a company of which more than 50% of the voting power for the election of directors is held by an individual, a group, or another company) from the requirements of certain corporate governance rules, including Nasdaq’s Majority Independent Board requirement. Nasdaq has been informed that the Company is a “controlled company” and has withdrawn its notice. Despite t”
MDH Acquisition Corp. received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).
“mmenced trading on the OTC Pink under the symbol “MDHA W”; the Company previously announced that the New York Stock Exchange (the “ NYSE ”) notified the Company, that the NYSE determined to commence proceedings to delist the Warrants, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Common Stock and units will continue to be listed on the NYSE. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the under”
Cohn Robbins Holdings Corp. received a nyse delisting notice notice regarding market value (rules 802.01B).
“y Securities ”) of Cohn Robbins Holdings Corp. (the “ Company ”) from the NYSE. On November 10, 2022, the NYSE notified the Company in writing of the determination to suspend trading and commence proceedings. The notification states that NYSE Regulation reached its determination pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day perio”
Starry Group Holdings, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“November 8, 2022, Starry Group Holdings, Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other cont”
Northern Star Investment Corp. III received a nyse delisting notice notice regarding other (rules 802.01D).
“November 11, 2022, Northern Star Investment Corp. III (the “ Company”) received a written notice (the “ Notice”) from the staff of NYSE Regulation (the “ Staff” ) of the New York Stock Exchange (“ NYSE”) indicating that the Staff has determined that the Company’s warrants, each warrant exercisable for one share of Class A Common Stock of the Company (the “ Warrants” ), are no longer suitable for listing on the NYSE based on “abnormally low” price levels, pursuant to Section 802.01D of the NYSE Listed Company Manual. As a result, the Staff has determined to commence proceedings to delist the Wa”
Hyperfine, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(a)(2), 5605(b)(1), 5605(b)(1)(A)).
“October 24, 2022, Hyperfine, Inc. (the “Company”) believes that Maria Sainz, a current director of the Company and a member of the audit committee of the board of directors of the Company (the “Board”), may no longer be considered an Independent Director as defined in Nasdaq Listing Rule 5605(a)(2). As a result of Ms. Sainz’s no longer being considered an Independent Director, on October 24, 2022, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications staff (the “Nasdaq Staff”) that the Company is not currently in compliance with the Majority Independent Board requi”
Fast Radius, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
“November 9, 2022, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock and warrants to purchase common stock (the “Securities”) will be delisted from Nasdaq. In addition, as previously disclosed, on June 9, 2022, the Company received written notice (the “Bid Price Notice”) from Nasdaq notifying the Company that it was not in”
MDH Acquisition Corp. received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).
“$0.0001 per share (the “Class A Common Stock”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “MDH.WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Common Stock and units will continue on the NYSE. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereun”
Kaleyra, Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).
“November 7, 2022, Kaleyra, Inc. (the “Company”), received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing criteria set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Company intends to respond to the NYSE within ten business days of receipt of the Notice with respect to its intent to cure the deficiency, as required by S”
CAMBER ENERGY, INC. received a nyse_american deficiency notice notice regarding minimum bid price (rules 1003(f)(v)).
“November 7, 2022, Camber Energy Inc. (the “ Company ”) received a deficiency letter (the “ Deficiency Letter ”) from the NYSE American LLC (the “ NYSE American ”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(f)(v) of the NYSE American Company Guide because its shares of common stock, par value $0.001 per share (the “ Common Stock ”) have been selling for a substantial period of time at a low price per share, which NYSE American determined to be a 30 day trading average price of less than $0.20 per share. As require”
TUESDAY MORNING CORP/DE received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2), 5605(c)(4)(B)).
“November 7, 2022, the Company notified Nasdaq of Mr. Berger’s appointment as Chief Executive Officer and resignation from the Audit Committee and the resulting non-compliance with Nasdaq Listing Rule 5605(c)(2). The Company also received a letter from Nasdaq indicating the Company was not in compliance with Nasdaq Listing Rule 5605 and noting that the Company would, in accordance with Nasdaq Listing Rule 5605(c)(4)(B), have a cure period until the earlier of its next annual meeting of shareholders or May 3, 2023 to regain compliance. The Company intends to appoint an additional independent dir”
Fusion Acquisition Corp. II received a nyse delisting notice notice regarding other (rules 802.01D).
“0.0001 per share (the “Class A Common Stock”), at a price of $11.50 per share, and listed to trade on the NYSE under the symbol “FSNB WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A Common Stock and units will continue on the NYSE. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned here”
Simon Property Group Acquisition Holdings, Inc. received a nyse delisting notice notice regarding other (rules 802.01D).
“November 10, 2022, the New York Stock Exchange (the “NYSE”) notified Simon Property Group Acquisition Holdings, Inc. (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants from the NYSE and that trading in the Company’s warrants would be suspended immediately, due to trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. The Company does not intend to appeal the NYSE’s determination. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this”
Catcha Investment Corp received a nyse delisting notice notice regarding other (rules 802.01D).
“November 4, 2022, the New York Stock Exchange (the “NYSE”) notified Catcha Investment Corp (the “Company”), and publicly announced, that the NYSE determined to commence proceedings to delist the Company’s warrants, each whole warrant exercisable for one Class A ordinary share and listed to trade on NYSE under the symbol “CHAA WS” (the “Warrants”), from the NYSE and that trading in the Warrants would be suspended immediately, due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual. Trading in the Company’s Class A ordinary shares under the symb”
iPower Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“November 9, 2022, iPower Inc., a Nevada corporation (the “Company”), received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock was trading below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The notification has no immediate effect on the Company’s Nasdaq listing and the Company’s co”
HC LIQUIDATING, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 4, 2022, HyreCar Inc. (the “Company”) received a letter (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecu”
ALKALINE WATER Co INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“November 8, 2022, the Company received a determination letter (the "Letter") from the Staff stating that the Company has not regained compliance with the Minimum Bid Price Rule and is not eligible for a second 180 day period as the Company does not comply with the US$5,000,000 minimum stockholders' equity initial listing requirement for The Nasdaq Capital Market. The Letter stated that, unless the Company requests an appeal of this determination no later than 4:00 p.m. (Eastern time) on November 15, 2022, the Staff has determined that the Company's common stock will be scheduled for delisting”
Akebia Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“a minimum of 10 consecutive business days as required under the Compliance Period Rule, the Staff will provide written notification to the Company that it complies with the Bid Price Requirement, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(H). If the Company does not regain compliance with the Bid Price Requirement by the Extended Compliance Date, the Staff will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the Staff’s delisting determination to a Na”
Axe Compute Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“November 10, 2022, Nasdaq notified the Company that while the Company had not regained compliance with the Minimum Bid Price Requirement, it is eligible for an additional 180-day calendar period, or until May 8, 2023, to regain compliance. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and the Company’s written notice to Nasdaq of its intention to cure the deficiency d”
AlerisLife Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing s”
Quanergy Systems, Inc. received a nyse delisting notice notice regarding market value (rules 802.01B).
“November 8, 2022, Quanergy Systems, Inc. (the “Company”) received a letter from the staff of NYSE Regulation notifying the Company that it had determined to commence proceedings to delist the Company’s common stock (NYSE:QNGY) and the Company’s warrants to purchase common stock (NYSE:QNGY WS) from the New York Stock Exchange (“NYSE”). Trading in these securities was suspended after the market close on the NYSE on November 8, 2022. NYSE Regulation reached its decision to delist these securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below”
Verastem, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“November 4, 2022, Verastem, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Complian”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.